As the clock ticks on top-line Phase III data from Actelion Ltd. with Tracleer (bosentan) in idiopathic pulmonary fibrosis, the FDA last week put InterMune Inc. on notice that an advisory panel in March will take up the case of its compound, pirfenidone, which stands a regulatory step ahead in the race to the IPF market.